Lauren E. Gartenhaus

This study shows that suppressing PP2A-B56α promotes EMT in EGFR mutant NSCLC by reducing epithelial markers and increasing mesenchymal markers, leading to migratory and invasive phenotypes.

This study shows that activating PP2A-B56 in PDAC increases EGFR signaling and promotes tumor growth, suggesting a new therapeutic target.

The paper shows that loss of miRNA processing drives angiosarcoma and that enoxacin enhances miRNA expression, reducing tumor cell viability and migration.

This study shows that PP2A activation inhibits macropinocytosis and induces cell death in pancreatic ductal adenocarcinoma, suggesting PP2A activators could be used with metabolic inhibitors as a new therapeutic strategy.

This study identifies miR-497 as a tumor suppressor in angiosarcoma by regulating target genes like CCND2, CDK6, and VAT1, with VAT1 inhibition reducing tumor migration.